WO2007127011A2 - Apparatus and method for filtration to enhance the detection of peaks - Google Patents
Apparatus and method for filtration to enhance the detection of peaks Download PDFInfo
- Publication number
- WO2007127011A2 WO2007127011A2 PCT/US2007/007855 US2007007855W WO2007127011A2 WO 2007127011 A2 WO2007127011 A2 WO 2007127011A2 US 2007007855 W US2007007855 W US 2007007855W WO 2007127011 A2 WO2007127011 A2 WO 2007127011A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hole array
- samples
- array filter
- layer
- filtered
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 121
- 238000001914 filtration Methods 0.000 title claims description 53
- 238000001514 detection method Methods 0.000 title claims description 17
- 201000010099 disease Diseases 0.000 claims abstract description 100
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 100
- 239000013060 biological fluid Substances 0.000 claims abstract description 60
- 238000001819 mass spectrum Methods 0.000 claims abstract description 53
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 230000004044 response Effects 0.000 claims abstract description 23
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 13
- 230000002708 enhancing effect Effects 0.000 claims abstract description 7
- 210000002966 serum Anatomy 0.000 claims description 39
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 29
- 201000005202 lung cancer Diseases 0.000 claims description 29
- 208000020816 lung neoplasm Diseases 0.000 claims description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000003550 marker Substances 0.000 claims description 21
- 210000002700 urine Anatomy 0.000 claims description 21
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 16
- 206010005003 Bladder cancer Diseases 0.000 claims description 12
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 12
- 239000000377 silicon dioxide Substances 0.000 claims description 12
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 10
- 230000035945 sensitivity Effects 0.000 claims description 9
- 229910052681 coesite Inorganic materials 0.000 claims description 8
- 229910052906 cristobalite Inorganic materials 0.000 claims description 8
- 229910052682 stishovite Inorganic materials 0.000 claims description 8
- 229910052905 tridymite Inorganic materials 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 6
- 210000002381 plasma Anatomy 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 42
- 239000000758 substrate Substances 0.000 description 36
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 20
- 239000010410 layer Substances 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- 229920002521 macromolecule Polymers 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 239000011159 matrix material Substances 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- -1 but not limited to Substances 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 150000001720 carbohydrates Chemical class 0.000 description 13
- 235000014633 carbohydrates Nutrition 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 239000002777 nucleoside Substances 0.000 description 12
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 12
- 229920001282 polysaccharide Polymers 0.000 description 12
- 239000005017 polysaccharide Substances 0.000 description 12
- 150000003431 steroids Chemical class 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- 239000012472 biological sample Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 229910052710 silicon Inorganic materials 0.000 description 8
- 239000010703 silicon Substances 0.000 description 8
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108090000371 Esterases Proteins 0.000 description 6
- 102000007474 Multiprotein Complexes Human genes 0.000 description 6
- 108010085220 Multiprotein Complexes Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 102000007079 Peptide Fragments Human genes 0.000 description 6
- 108010033276 Peptide Fragments Proteins 0.000 description 6
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 6
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 239000000370 acceptor Substances 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000340 anti-metabolite Effects 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 229940100197 antimetabolite Drugs 0.000 description 6
- 239000002256 antimetabolite Substances 0.000 description 6
- 239000003080 antimitotic agent Substances 0.000 description 6
- 150000001735 carboxylic acids Chemical class 0.000 description 6
- 231100000357 carcinogen Toxicity 0.000 description 6
- 239000003183 carcinogenic agent Substances 0.000 description 6
- 235000021466 carotenoid Nutrition 0.000 description 6
- 150000001747 carotenoids Chemical class 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000003763 chloroplast Anatomy 0.000 description 6
- 239000005515 coenzyme Substances 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000002532 enzyme inhibitor Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 229910021645 metal ion Inorganic materials 0.000 description 6
- 230000002438 mitochondrial effect Effects 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 239000003471 mutagenic agent Substances 0.000 description 6
- 231100000707 mutagenic chemical Toxicity 0.000 description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 description 6
- 125000003835 nucleoside group Chemical group 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 150000003014 phosphoric acid esters Chemical class 0.000 description 6
- 239000005648 plant growth regulator Substances 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 150000004032 porphyrins Chemical class 0.000 description 6
- 238000011045 prefiltration Methods 0.000 description 6
- 230000009145 protein modification Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- 229920001059 synthetic polymer Polymers 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 108090001060 Lipase Proteins 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 5
- 239000004367 Lipase Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000002555 ionophore Substances 0.000 description 5
- 230000000236 ionophoric effect Effects 0.000 description 5
- 235000019421 lipase Nutrition 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000003914 blood derivative Substances 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical class OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000010894 electron beam technology Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000011241 protective layer Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000001312 dry etching Methods 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001039 wet etching Methods 0.000 description 2
- 240000008791 Antiaris toxicaria Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 229910021419 crystalline silicon Inorganic materials 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the use of the filter accentuated the differences between the presence of peaks in. the pre-filter and post-filter chromatograms for pancreatic cancer. These results will be apparent to one of ordinary skill in the art by examining FIGS. 7-1 to 7-42 in the same manner as the examination of the results of the lung cancer screening discussed above. Clearly, the use of the filter enhanced the detection of the relevant peaks.
- nucleic acid complexes protein-DNA complexes, receptor-ligand complexes, enzyme-substrate, enzyme inhibitors, peptide complexes, protein complexes, carbohydrate complexes, and polysaccharide complexes
- small biological molecules such as amino acids, nucleotides, nucleosides, sugars, steroids, lipids, metal ions, drugs, hormones, amides, amines, carboxylic acids, vitamins and coenzymes, alcohols, aldehydes, ketones, fatty acids, porphyrins, carotenoids, plant growth regulators, phosphate esters and nucleoside diphospho-sugars, synthetic small molecules such as pharmaceutically or therapeutically effective agents, monomers, peptide analogs, steroid analogs, inhibitors, mutagens, carcinogens, antimitotic drugs, antibiotics, ionophores, antimetabolites, amino acid analogs, antibacterial agents, transport inhibitors, surface-active agents (surfactants), mitochondrial and
- the serum was diluted 1 : 10 in 0.1% n-Octyl ⁇ -D- Glucopyranoside.
- the micro tubes were cut individually from Micro Amp 8 strip tubes. A hole was made in the bottom part of the micro tube by using a needle (Becton Dickinson 20Gl) having a diameter of 0.9 mm or less.
- the micro tube with hole was placed on the metal plate of a gel-pak suction apparatus (air pump) and the hole was adjusted to the same air-flow direction of the air pump.
- the filter was placed on the top of the micro tube. 20 ⁇ l of serum was loaded on the upper part of filter. The serum solution spread out, filling the inner square of filter. The negative air flow was applied by pumping the air pump manually.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Wood Science & Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Genetics & Genomics (AREA)
- Sustainable Development (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009503017A JP2009531716A (ja) | 2006-03-29 | 2007-03-29 | ピークの検出を向上させる濾過器具および方法 |
| EP07754381A EP2013800A2 (en) | 2006-03-29 | 2007-03-29 | Apparatus and method for filtration to enhance the detection of peaks |
| US12/225,704 US20100140465A1 (en) | 2006-03-29 | 2007-03-29 | Apparatus and Method for Filtration to Enhance the Detection of Peaks |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/391,471 | 2006-03-29 | ||
| US11/391,469 | 2006-03-29 | ||
| US11/391,182 | 2006-03-29 | ||
| US11/391,183 | 2006-03-29 | ||
| US11/391,471 US20070231917A1 (en) | 2006-03-29 | 2006-03-29 | Apparatus and method for filtration to enhance the detection of peaks |
| US11/391,183 US20070231916A1 (en) | 2006-03-29 | 2006-03-29 | Apparatus and method for filtration to enhance the detection of peaks |
| US11/391,469 US20070238193A1 (en) | 2006-03-29 | 2006-03-29 | Apparatus and method for filtration to enhance the detection of peaks |
| US11/391,182 US20070231915A1 (en) | 2006-03-29 | 2006-03-29 | Apparatus and method for filtration to enhance the detection of peaks |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/441,239 A-371-Of-International US8192503B2 (en) | 2006-09-15 | 2007-09-14 | Method and apparatus for decreasing build height of prosthetic products |
| US13/480,193 Division US8992630B2 (en) | 2006-09-15 | 2012-05-24 | Method and apparatus for decreasing build height of prosthetic products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007127011A2 true WO2007127011A2 (en) | 2007-11-08 |
| WO2007127011A3 WO2007127011A3 (en) | 2008-12-04 |
Family
ID=38656080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2007/007855 WO2007127011A2 (en) | 2006-03-29 | 2007-03-29 | Apparatus and method for filtration to enhance the detection of peaks |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2013800A2 (ko) |
| JP (1) | JP2009531716A (ko) |
| KR (1) | KR20090028684A (ko) |
| WO (1) | WO2007127011A2 (ko) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2623984A1 (en) * | 2012-01-03 | 2013-08-07 | National Cancer Center | Apparatus for screening cancer |
| US10042983B2 (en) | 2012-01-03 | 2018-08-07 | National Cancer Center | Apparatus for cancer diagnosis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060219558A1 (en) * | 2005-04-05 | 2006-10-05 | Hafeman Dean G | Improved Methods and Devices for Concentration and Fractionation of Analytes for Chemical Analysis including Matrix-Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry (MS) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ516848A (en) * | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
| GB0122200D0 (en) * | 2001-09-14 | 2001-10-31 | James Peter | Concentration of protein and/or peptide samples |
| CA2516182A1 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Expression profiles for breast cancer and methods of use |
| WO2005036132A2 (en) * | 2003-10-10 | 2005-04-21 | Protein Discovery, Inc. | Methods and devices for concentration and purification of analytes for chemical analysis including matrix-assisted laser desorption/ionization (maldi) mass spectrometry (ms) |
| JP2005156249A (ja) * | 2003-11-21 | 2005-06-16 | Toray Ind Inc | 生体成分分離溶液 |
-
2007
- 2007-03-29 KR KR1020087026321A patent/KR20090028684A/ko not_active Application Discontinuation
- 2007-03-29 WO PCT/US2007/007855 patent/WO2007127011A2/en active Application Filing
- 2007-03-29 JP JP2009503017A patent/JP2009531716A/ja active Pending
- 2007-03-29 EP EP07754381A patent/EP2013800A2/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060219558A1 (en) * | 2005-04-05 | 2006-10-05 | Hafeman Dean G | Improved Methods and Devices for Concentration and Fractionation of Analytes for Chemical Analysis including Matrix-Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry (MS) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2623984A1 (en) * | 2012-01-03 | 2013-08-07 | National Cancer Center | Apparatus for screening cancer |
| US10042983B2 (en) | 2012-01-03 | 2018-08-07 | National Cancer Center | Apparatus for cancer diagnosis |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2013800A2 (en) | 2009-01-14 |
| WO2007127011A3 (en) | 2008-12-04 |
| KR20090028684A (ko) | 2009-03-19 |
| JP2009531716A (ja) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2807271B1 (en) | System for detecting infection in synovial fluid | |
| Cho et al. | Biomarker Characterization by MALDI–TOF/MS | |
| EP1904853A1 (en) | Method for diagnosing multiple sclerosis | |
| DE112012000821T5 (de) | Zusammensetzung und Verfahren zum Diagnostizieren von Eierstockkrebs | |
| EP2010895A2 (en) | Apparatus and method for predicting disease | |
| WO2013090857A1 (en) | Identification of two novel biomarkers for niemann-pick disease type c | |
| KR102125190B1 (ko) | 패혈증 진단을 위한 질량 분석용 샘플 플레이트 및 이를 이용한 질량 분석 방법 | |
| EP1660673A2 (en) | Method for diagnosing head and neck squamous cell carcinoma | |
| WO2007127011A2 (en) | Apparatus and method for filtration to enhance the detection of peaks | |
| US20070231916A1 (en) | Apparatus and method for filtration to enhance the detection of peaks | |
| US20070231917A1 (en) | Apparatus and method for filtration to enhance the detection of peaks | |
| CN112305122B (zh) | 代谢物标志物及其在疾病中的应用 | |
| US20110008901A1 (en) | Apolipoprotein ciii in pre- and type 2 diabetes | |
| Yang et al. | Evolving platforms for clinical mass spectrometry | |
| US20070231915A1 (en) | Apparatus and method for filtration to enhance the detection of peaks | |
| US20070238193A1 (en) | Apparatus and method for filtration to enhance the detection of peaks | |
| US20100140465A1 (en) | Apparatus and Method for Filtration to Enhance the Detection of Peaks | |
| WO2023016416A1 (zh) | 用于nmosd预测或复发监测的生物标志物及其应用 | |
| CN112147344B (zh) | 动脉粥样硬化性脑梗死的代谢标志物及其在诊疗中的应用 | |
| EP1477803A1 (en) | Serum protein profiling for the diagnosis of epithelial cancers | |
| WO2004102189A1 (en) | Biomarkers for the differential diagnosis of pancreatitis and pancreatic cancer | |
| WO2021245527A2 (en) | Real-time tracing of cytokine storm in blood serum of covid-19 patients | |
| US20110008799A1 (en) | Phenotypic ratio of serum amyloid in pre- and type 2 diabetes | |
| CN115372628B (zh) | 与转甲状腺素蛋白淀粉样变性相关的代谢标志物及其应用 | |
| CN114487214B (zh) | 一种区分良性前列腺增生和前列腺炎的生物标志物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200780020065.0 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07754381 Country of ref document: EP Kind code of ref document: A2 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2009503017 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007754381 Country of ref document: EP Ref document number: 1020087026321 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12225704 Country of ref document: US |